Please try another search
BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity. The company markets two strains of probiotic bacteria, which include BLIS K12, a probiotic supplement to support ear, nose, and throat health of young children, as well as for improving immunity and bad breath; BLIS M18, an oral probiotic to support teeth, gums, and dental health; and BLIS Q24, a probiotic supplement to balance and restore the skin microbiome, restoring the health, clarity, and radiance. It has operations in New Zealand, Asia Pacific, Europe, the Middle East, Africa, and North America. The company was incorporated in 2000 and is based in Dunedin, New Zealand.
Name | Age | Since | Title |
---|---|---|---|
Geoffrey Plunket | - | 2018 | Independent Chairman |
Jorn Andreas | 43 | 2023 | Non-Executive Director |
Barry C. Richardson | - | 2006 | Independent Non-Executive Director |
Alison Stewart | 66 | 2018 | Independent Non-Executive Director |
Anita Johansen | 52 | 2024 | Non-Executive Director |
Amelia McCammon | - | 2021 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review